| __timestamp | Apellis Pharmaceuticals, Inc. | Blueprint Medicines Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 7890000 |
| Thursday, January 1, 2015 | 6356782 | 14456000 |
| Friday, January 1, 2016 | 4303743 | 19218000 |
| Sunday, January 1, 2017 | 10463151 | 27986000 |
| Monday, January 1, 2018 | 22639184 | 47928000 |
| Tuesday, January 1, 2019 | 67046483 | 96388000 |
| Wednesday, January 1, 2020 | 139401000 | 157743000 |
| Friday, January 1, 2021 | 176771000 | 195293000 |
| Saturday, January 1, 2022 | 277163000 | 237374000 |
| Sunday, January 1, 2023 | 500815000 | 295141000 |
| Monday, January 1, 2024 | 359272000 |
Unleashing the power of data
In the competitive world of biotechnology, managing operational expenses is crucial for success. Over the past decade, Apellis Pharmaceuticals, Inc. and Blueprint Medicines Corporation have demonstrated contrasting strategies in their Selling, General, and Administrative (SG&A) expenses.
From 2014 to 2023, Apellis Pharmaceuticals saw a staggering increase in SG&A expenses, growing from approximately $2.9 million to over $500 million, marking a growth of over 17,000%. In contrast, Blueprint Medicines started with higher initial expenses of around $7.9 million in 2014, reaching nearly $295 million by 2023, a growth of about 3,600%.
This divergence highlights Apellis's aggressive expansion strategy, while Blueprint's steadier growth suggests a more measured approach. Investors and industry analysts can glean insights into each company's operational focus and strategic priorities by examining these trends.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
Amgen Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Blueprint Medicines Corporation Trends and Insights
Halozyme Therapeutics, Inc. and Apellis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ACADIA Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and PTC Therapeutics, Inc.
Blueprint Medicines Corporation and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Blueprint Medicines Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Ultragenyx Pharmaceutical Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Wave Life Sciences Ltd. Trends and Insights